List of Excipients in Branded Drug NAPRELAN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA	NAPRELAN	naproxen sodium	16590-242	ANHYDROUS CITRIC ACID
STAT RX USA	NAPRELAN	naproxen sodium	16590-242	CELLULOSE, MICROCRYSTALLINE
STAT RX USA	NAPRELAN	naproxen sodium	16590-242	CROSPOVIDONE
STAT RX USA	NAPRELAN	naproxen sodium	16590-242	HYPROMELLOSE

NAPRELAN Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

NAPRELAN is a prescription extended-release tablet containing naproxen sodium. Its commercial value comes from once-daily delivery of a high-dose nonsteroidal anti-inflammatory drug, while its principal formulation challenge is controlling release without compromising bioavailability, tablet manufacturability, or gastrointestinal tolerability. The strongest opportunities are generic extended-release development, differentiated modified-release products, and excipient-enabled improvements in tablet size, dissolution control, and manufacturing efficiency.

What is NAPRELAN and how does its formulation work?

NAPRELAN contains naproxen sodium in 375 mg, 500 mg, and 750 mg extended-release tablets. It is approved for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The product is administered once daily, with total daily dosing adjusted by indication and patient response. [1]

NAPRELAN differs from immediate-release naproxen and naproxen sodium products because it uses a controlled-release tablet platform rather than relying on rapid dissolution of the active ingredient. The formulation must provide:

• A controlled release profile over the dosing interval.
• Adequate systemic exposure under fasting and fed conditions.
• Acceptable mechanical strength and low friability.
• Consistent dissolution across commercial batches.
• Protection against dose dumping caused by food, alcohol, tablet defects, or excessive mechanical stress.

The public label identifies inactive ingredients including colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, povidone, sodium lauryl sulfate, and talc. The precise functional architecture of the controlled-release system, including processing parameters, particle-size controls, coating conditions, and dissolution specifications, is not fully disclosed in the product label. [1]

What excipients are used in NAPRELAN?

The listed excipients perform conventional formulation functions, although the commercial performance of NAPRELAN depends on their interaction and manufacturing process.

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Supports tablet mass and cost-efficient manufacture
Povidone	Binder	Improves granule strength and content uniformity
Crospovidone	Disintegrant or release-modifying structural component	Can control internal tablet porosity and improve reproducibility
Magnesium stearate	Lubricant	Reduces ejection force but can slow wetting if overused
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and reduces manufacturing variability
Sodium lauryl sulfate	Wetting agent and dissolution aid	Helps manage hydrophobic drug-particle behavior
Talc	Processing aid, anti-adherent, or coating-related excipient	Supports tablet handling and manufacturing robustness

Naproxen sodium is more water-soluble than naproxen, which creates a formulation problem for extended release. A highly soluble salt can release too quickly unless the matrix, coating, tablet porosity, or granulation structure provides sufficient resistance to dissolution. The excipient strategy therefore cannot focus only on increasing solubility. It must balance wetting with controlled diffusion.

What is the role of sodium lauryl sulfate?

Sodium lauryl sulfate can improve wetting and reduce variability caused by hydrophobic surfaces. In a controlled-release naproxen sodium tablet, excessive wetting enhancement could accelerate drug release and undermine the extended-release profile.

For a generic or follow-on product, the amount and distribution of sodium lauryl sulfate can affect:

• Initial burst release.
• Fed-versus-fasted pharmacokinetics.
• Dissolution sensitivity to agitation.
• Interaction with magnesium stearate.
• Stability under high humidity.
• Drug release after tablet subdivision or mechanical damage.

This excipient is therefore a high-impact variable rather than a routine formulation input.

What is the role of crospovidone in an extended-release tablet?

Crospovidone is commonly used as a superdisintegrant, but its function in a modified-release matrix can be more complex. Its capillary action may increase water penetration and create internal pathways for dissolution. That can improve release consistency, but it can also produce an undesirable early release phase if the tablet structure lacks adequate release control.

A development program should characterize crospovidone by grade, particle size, moisture content, and concentration. Substitution with another disintegrant can materially change dissolution even when the nominal excipient percentage remains constant.

What excipient strategy is best for a generic NAPRELAN product?

A generic developer should use a risk-based formulation strategy focused on dissolution matching and pharmacokinetic equivalence rather than simple qualitative and quantitative copying.

Matrix-based strategy

A hydrophilic matrix using a polymer such as hypromellose can provide release control through hydration, gel formation, diffusion, and erosion. This approach is commercially attractive because it can use conventional direct compression or wet granulation equipment.

Key variables include:

• Polymer viscosity grade.
• Polymer concentration.
• Tablet hardness.
• Granule density.
• Drug-to-polymer ratio.
• Lubrication time.
• Compression force.
• Tablet porosity.

The main risk is that a hydrophilic matrix may produce a release profile that changes substantially with food, agitation, tablet size, or scale-up conditions.

Coated-matrix strategy

A coated tablet can combine an internal matrix with a functional film. Film polymers may include ethylcellulose, cellulose acetate, methacrylate copolymers, or other water-permeable materials. Coating can reduce burst release and provide additional protection against manufacturing variability.

The commercial disadvantages are higher process complexity, longer cycle times, solvent or aqueous-coating development, and increased need for coating-uniformity controls.

Multiparticulate strategy

Pellets, beads, or granules with functional coatings can provide more consistent gastrointestinal distribution and lower sensitivity to localized tablet damage. Multiparticulates also create opportunities for sprinkle administration or smaller-unit dosing.

The principal barriers are:

• Higher manufacturing cost.
• More complex dose uniformity testing.
• Greater packaging requirements.
• More difficult scale-up.
• Potentially more demanding in vitro-in vivo correlation work.

Multiparticulates are better suited to differentiated products than to the lowest-cost generic strategy.

What formulations are protected by NAPRELAN-related intellectual property?

NAPRELAN-related intellectual property historically has focused on controlled-release delivery of naproxen or naproxen sodium rather than on the active ingredient itself. The relevant claim categories can include:

1. Controlled-release tablet compositions.
2. Polymer matrices or coated dosage forms.
3. Specific dissolution profiles.
4. Manufacturing processes.
5. Once-daily dosing methods.
6. Salt forms and release-control combinations.
7. Bioequivalence-linked formulation parameters.

The core naproxen sodium compound is an old active ingredient, so commercial protection is more likely to depend on formulation, process, method-of-use, regulatory exclusivity, trademarks, and manufacturing know-how than on basic compound claims.

Patent status must be assessed by patent family, claim scope, terminal disclaimers, maintenance status, and jurisdiction. A historical patent associated with NAPRELAN does not necessarily remain enforceable, and an expired formulation patent does not eliminate trade-secret protection for manufacturing parameters.

When does NAPRELAN lose exclusivity?

NAPRELAN’s active ingredient is long off patent. The principal commercial question is whether any enforceable formulation or method-of-use claims remain relevant in the target market.

For U.S. products, the key records are:

• FDA Orange Book patent listings.
• FDA Regulatory Exclusivity information.
• The NAPRELAN product label.
• ANDA approvals for naproxen sodium extended-release tablets.
• USPTO patent maintenance and assignment records.
• Federal district court and Federal Circuit litigation records. [1,2]

The product is not a biologic and has no biosimilar pathway. Competition would arise through an abbreviated new drug application, an authorized generic, a reformulated prescription product, or an over-the-counter or prescription immediate-release alternative.

The absence of a listed Orange Book patent would reduce the likelihood of a conventional Paragraph IV patent dispute, but it would not eliminate risk from unlisted process patents, formulation patents, trade secrets, or regulatory exclusivity issues.

What is the Orange Book status of NAPRELAN?

NAPRELAN is an FDA-approved small-molecule drug product subject to the Orange Book framework. The Orange Book determines whether listed patents can support a Paragraph IV certification and potential patent litigation under the Hatch-Waxman Act. [2]

For commercial diligence, the relevant questions are:

Issue	Business impact
Listed formulation patent	Can delay or complicate ANDA approval
Listed method-of-use patent	May require a Section viii carve-out or label strategy
No current listed patent	Reduces Orange Book-based launch barriers
Pediatric exclusivity	Can extend certain regulatory protections
30-month stay	May delay approval after qualifying patent litigation
First-filer status	May create 180-day generic exclusivity
Authorized generic	Can reduce first-generic price advantage

An ANDA developer should not assume that an old branded formulation is freely replicable without reviewing the current Orange Book, FDA product-specific guidance, and patent-family records.

What Paragraph IV challenges could affect NAPRELAN?

A Paragraph IV challenge would assert that a listed patent is invalid, unenforceable, or not infringed. For an extended-release naproxen sodium product, the most probable targets would be formulation and dissolution claims rather than active-ingredient claims.

A challenger would typically focus on:

• Prior-art controlled-release NSAID formulations.
• Obviousness of combining naproxen sodium with known matrix excipients.
• Lack of written description for broad excipient ranges.
• Failure of the claims to distinguish over earlier modified-release tablets.
• Non-infringement based on a different polymer, coating, or process.
• Lack of clinical or pharmacokinetic evidence supporting functional claim limitations.

The strongest branded claims would be those tied to a narrow, reproducible release architecture or a specific manufacturing process that competitors cannot readily design around. Broad claims covering routine excipient categories are more vulnerable to prior-art and obviousness attacks.

How strong is the NAPRELAN patent estate?

The likely strength of the estate is moderate to weak at the active-ingredient level and potentially stronger at the formulation and process level.

Protection layer	Likely strength	Reason
Naproxen sodium compound	Low	Mature, widely used active ingredient
Once-daily indication	Low to moderate	Potential overlap with prior art and labeling limitations
Controlled-release formulation	Moderate	Strength depends on claim specificity and surviving patent term
Manufacturing process	Moderate to strong	Process parameters may be difficult to detect and replicate
Dissolution profile	Moderate	Useful if the claims are technically specific and valid
Trademark and product recognition	Moderate	Supports brand retention but does not block generic entry
Trade secrets	Potentially strong	Granulation, coating, and scale-up controls may remain confidential

The most defensible commercial assets may be process know-how, supplier qualification, dissolution-control expertise, and regulatory history rather than broad patent claims.

What FDA regulatory hurdles apply to a generic NAPRELAN product?

A generic developer must demonstrate pharmaceutical equivalence and bioequivalence through the ANDA pathway. Extended-release products generally require more extensive evidence than immediate-release tablets because release rate and food effects can materially change exposure.

The development program should address:

• Strength-specific dissolution testing.
• Comparative dissolution across multiple media and agitation conditions.
• Fasting bioequivalence.
• Fed bioequivalence.
• Single-dose pharmacokinetic parameters, including AUC and Cmax.
• Dose proportionality or strength bracketing where applicable.
• Alcohol-induced dose-dumping evaluation, if required.
• Stability under long-term and accelerated conditions.
• Impurity and degradation-product control.
• Comparative product quality and robustness.

FDA product-specific guidance should be checked for the current expectations applicable to naproxen sodium extended-release tablets. [3] The major technical risk is not simply failure to match average dissolution. It is failure to match the entire release profile under physiologically relevant and stress conditions.

What commercial opportunities exist for NAPRELAN excipients?

The opportunity set extends beyond a direct generic.

1. Low-cost generic extended-release tablets

The largest addressable opportunity is a conventional ANDA product using widely available excipients and standard tablet equipment. Cost advantages can come from:

• Direct compression rather than wet granulation.
• Lower coating weight.
• Fewer excipient grades.
• Reduced process time.
• Improved tablet tensile strength at lower compression force.
• Reduced dependence on specialty polymers.

The developer must protect dissolution performance during scale-up. A low-cost formula that requires narrow manufacturing tolerances may not be commercially attractive.

2. Smaller tablets

NAPRELAN is a high-dose product. Tablet size is a patient and manufacturing concern, particularly at the 750 mg strength. Higher-density excipients, improved granulation, and optimized compression can reduce tablet volume.

Potential approaches include:

• Spray-dried lactose or mannitol.
• Co-processed microcrystalline cellulose systems.
• High-density dibasic calcium phosphate, subject to compatibility and dissolution testing.
• Granulation methods that improve packing efficiency.
• Reduced coating thickness through more efficient release-control polymers.

A smaller tablet could support a differentiated product claim, although the commercial value depends on whether the size reduction is clinically meaningful and legally protectable.

3. Sprinkle or multiparticulate dosage forms

A capsule containing controlled-release pellets could support patients with swallowing difficulty. It could also enable administration over soft food, subject to stability and dose-uniformity validation.

This opportunity has higher development cost but may support a new product profile that is less directly substitutable with a standard tablet.

4. Excipient-enabled dissolution consistency

A formulation using a more robust wetting system, lubricant control, or co-processed excipient could reduce batch-to-batch variation. The commercial value is strongest when the improvement reduces rejected batches, shortens testing, or enables manufacturing at multiple sites.

5. Sodium-conscious positioning

Naproxen sodium contains sodium, but the product’s sodium load is generally much lower than the tablet mass. A developer could assess whether a naproxen rather than naproxen sodium platform creates a clinically or commercially relevant sodium-reduction claim. The challenge is that naproxen has lower aqueous solubility, which can increase formulation complexity and may require a different release architecture.

6. Combination products

A controlled-release naproxen platform could be combined with gastroprotective or adjunctive therapies, but combination-product development would introduce new clinical, regulatory, patent, and safety requirements. The strongest near-term commercial case remains a standalone extended-release product.

Which companies are challenging NAPRELAN?

The relevant competitive set includes generic manufacturers with experience in extended-release tablets, NSAIDs, and complex oral dosage forms. Potential competitors include large ANDA companies, specialty generics manufacturers, and firms with controlled-release technology platforms.

Competitive diligence should examine:

• FDA approvals for naproxen sodium extended-release tablets.
• Current marketing status by strength.
• ANDA holders and manufacturing sites.
• Product discontinuation notices.
• Teva, Sandoz, Viatris, Amneal, Dr. Reddy's, Lupin, and other generic portfolios.
• Authorized-generic relationships.
• Wholesale acquisition cost and reimbursement status.
• Supply reliability and shortage history.

An approved ANDA does not guarantee sustained commercial competition. Extended-release products can have limited market participation because of manufacturing complexity, low reimbursement, and modest volume relative to immediate-release naproxen.

What revenue exposure does NAPRELAN create?

Standalone NAPRELAN revenue is difficult to isolate from public company reporting because branded naproxen products are often grouped within broader prescription pharmaceutical portfolios. The revenue exposure depends on:

• Current brand market share.
• Availability of approved generics.
• Payer substitution rules.
• Number of active suppliers.
• Price erosion after generic entry.
• Prescriber preference for once-daily dosing.
• Competition from immediate-release naproxen and over-the-counter products.

Once-daily dosing can preserve a niche after generic entry, but the price premium generally contracts sharply when therapeutically substitutable extended-release products become available.

What patent litigation and settlement risks affect NAPRELAN?

If a relevant Orange Book patent remains listed, a first ANDA filer could trigger Hatch-Waxman litigation and a possible 30-month stay. Settlement terms could include:

• A licensed generic launch date.
• An authorized-generic arrangement.
• No-challenge provisions, subject to antitrust constraints.
• Supply or manufacturing agreements.
• Restrictions on formulations or strengths.
• Launch rights tied to patent invalidation or expiration.

If no listed patent remains, litigation risk shifts toward trade-secret misappropriation, process patents, product liability, or regulatory disputes. Process litigation is harder for a branded company because infringement may not be visible from the finished tablet.

How does NAPRELAN compare with immediate-release naproxen products?

Attribute	NAPRELAN	Immediate-release naproxen or naproxen sodium
Dosing	Once daily	Usually more frequent
Release control	Required	Not required
Formulation complexity	High	Low to moderate
Generic development cost	Higher	Lower
Dose-dumping risk	Relevant	Limited
Tablet size	Large at higher strengths	Usually smaller per unit
Food-effect sensitivity	Must be characterized	Generally less complex
Substitution risk	High from other ER products and IR regimens	High from OTC and prescription products
Patent value	Formulation and process driven	Limited active-ingredient value

NAPRELAN’s commercial differentiation is convenience, not a new pharmacologic mechanism. That limits durable pricing power but creates value for patients and prescribers who prefer once-daily NSAID dosing.

What generic launch scenarios exist for NAPRELAN?

Three launch scenarios are commercially relevant.

Early launch after patent clearance

A first or early ANDA entrant could obtain substantial share if few extended-release competitors are active. Price erosion would depend on the number of suppliers and whether an authorized generic is present.

At-risk launch

An ANDA holder could launch before final resolution of patent litigation. This creates potential damages exposure, injunction risk, and loss of launch economics if the branded company prevails.

Late, multi-source launch

Several generic suppliers could enter after patent expiry or settlement. This scenario produces faster price erosion and makes manufacturing cost, supply reliability, and contracting more important than formulation differentiation.

Key Takeaways

• NAPRELAN is an extended-release naproxen sodium tablet in 375 mg, 500 mg, and 750 mg strengths.
• The formulation challenge is controlling release of a relatively soluble sodium salt without creating burst release or food-related exposure changes.
• Publicly listed excipients include lactose monohydrate, povidone, crospovidone, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, and talc.
• The strongest generic-development priorities are dissolution matching, fed and fasting bioequivalence, dose-dumping control, and scale-up robustness.
• Patent value is likely concentrated in formulation and manufacturing claims, not the naproxen sodium active ingredient.
• NAPRELAN is subject to the U.S. small-molecule generic framework, not biosimilar regulation.
• The best commercial opportunities are low-cost ANDA development, smaller tablets, multiparticulate delivery, and excipient systems that improve dissolution consistency.
• Brand revenue protection is limited by the maturity of naproxen, competition from immediate-release products, and likely generic substitution.

FAQs

Can NAPRELAN tablets be reformulated with different excipients?

Yes. An ANDA product may use different inactive ingredients if it meets FDA requirements for safety, pharmaceutical equivalence, quality, dissolution, and bioequivalence. Different excipients can change release kinetics and may require additional development work.

Is naproxen sodium extended release difficult to manufacture?

Yes. The high dose, soluble salt form, and need for controlled release create sensitivity to granule density, lubricant level, tablet porosity, coating uniformity, and process scale. Extended-release dissolution must remain consistent across commercial batches.

Could a naproxen extended-release product replace NAPRELAN?

Potentially, but naproxen and naproxen sodium have different solubility and formulation properties. A naproxen product would require its own release-control strategy, bioequivalence assessment, labeling analysis, and regulatory pathway.

Are NAPRELAN excipients likely to support a patentable reformulation?

Possibly, but routine substitution of common excipients is unlikely to provide strong patent protection by itself. A stronger claim would generally require a technically defined composition, manufacturing process, dissolution profile, or clinically relevant performance advantage.

Does NAPRELAN have biosimilar competition?

No. NAPRELAN contains the small-molecule active ingredient naproxen sodium. Competition proceeds through generic-drug and reformulation pathways rather than the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). NAPRELAN (naproxen sodium) extended-release tablets: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2013). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Center for Drug Evaluation and Research.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.